TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00513110

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AMPD1 polymorphism
Description: Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine infusion
Description: Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Endotoxin 2ng/kg combined with saline infusion (0.9%)
Study: NCT04000789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate, Vitamin A, Vitamin E
Description: Eye drops consisting of combination of Sodium Hyaluronate, Vitamin A, Vitamin E will be . given to patients in control groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate, Vitamin A, Vitamin E
Description: Eye drops consisting of combination of Sodium Hyaluronate, Vitamin A, Vitamin E will be . given to patients in control groups

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Hyaluronate, Vitamin A, Vitamin E
Description: Eye drops consisting of combination of Sodium Hyaluronate, Vitamin A, Vitamin E will be . given to patients in control groups

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate, Vitamin A, Vitamin E
Description: Eye drops consisting of combination of Sodium Hyaluronate, Vitamin A, Vitamin E will be . given to patients in control groups
Study: NCT00427349

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 706
Description: AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the AM. AMG 706 was taken daily without breaks in treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: octreotide
Description: One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles.
Study: NCT02026921

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin, AUC5, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
Study: NCT02941705

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Allogeneic Derived Cells
Description: patients will have the CAP-1002 solution delivered through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Control Arm
Description: patients will receive the placebo through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
Study: NCT01460199

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-499
Description: 3 X 200 mg tablets (QD for 2 weeks)~3 x 200 mg tablets (BID for 2 weeks)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablets
Study: NCT03946137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest Therapy
Description: The sessions of chest therapy were based on airway clearance techniques (hyper manual insufflations, abdominal thoracic compressions and manually assisted cough)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Postural Hygiene
Description: Postural hygiene workshops were taught through a theoretical presentation with the help of slides and practical exercises in small groups (2-4 parents per group).
Study: NCT02324855

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chest physiotherapy plus usual care
Description: Subjects will perform daily chest physiotherapy during at least 30 minutes. Patients will perform a slow expiratory airway clearance technique combined with positive expiratory pressure device (Acapella device, Murray et al.) Each patient will receive 12 supervised professional sessions (once a month).
Study: NCT02437864

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Supplemental oxygen via nasal cannula
Study: NCT01553136

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Varenicline
Description: 0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: 0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
Study: NCT04350528

Intervention type: DRUG
Intervention: Chlorpromazine or Pentobarbital
Description: Sedation

Intervention type: DRUG
Intervention: Chlorpromazine or Pentobarbital
Description: Sedation
Study: NCT02768090

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skin Patch
Description: Sweat will be collected by applying a diagnostic skin patch to inflammatory and neoplastic cutaneous lesions for proteomic analysis with mass spectrometry.
Study: NCT01058070

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Torax Medical, Inc. LINX Reflux Management System
Description: Implantable device, Magnetic Esophageal Sphincter
Study: NCT04288986

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keep Achieving
Description: The 8-week group based activity programme will consist of 8 sessions each lasting 50 minutes.
Study: NCT02428712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FORE8394
Study: NCT03877536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genvoya 150Mg-150Mg-200Mg-10Mg Tablet
Description: Participants will receive 1 tablet per day throughout study duration (96 weeks).
Study: NCT02198443

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra)
Description: (TRUVADA) film-coated 200/245 mg tablet / day tablets (Kaletra) film-coated 200/50 mg tablets twice / day tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil
Description: Film-coated tablets of 150 mg of elvitegravir, cobicistat 150 mg, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil. One tablet once / day.
Study: NCT04647877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenytoin cream
Description: Phenytoin cream to be applied on the neuropathic pain area

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: phenytoin cream
Description: Phenytoin cream to be applied on the neuropathic pain area

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Description: Placebo cream to be applied on the neuropathic pain area
Study: NCT02822885

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Ultrasonography
Description: Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
Study: NCT04310085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-Lumefantrine 20 Mg-120 Mg Oral Tablet
Description: artemether-lumefantrine 6 x of 4 tablets at approximately 0, 8, 24, 36, 48 and 60 h

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PfSPZ-DVI Challenge
Description: 3200 P. falciparum Sporozoites by direct venous inoculation (DVI)
Study: NCT01550861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: in vitro maturation
Description: Maturation of immature oocytes in the laboratory following oocyte retrieval

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Polar Body Biopsy with preimplantation genetic screening
Description: Polar body biopsy is performed on the day that the oocyte is retrieved. Microarray analysis will will be performed and compared with FISH and microarray analysis of day 3 or day 5 biopsy.
Study: NCT03112889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Description: Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
Study: NCT03454802

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Passive Leg Raising
Description: See above

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Passive Leg Raising
Description: See above

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Passive Leg Raising
Description: See above
Study: NCT04752176

Intervention type: DEVICE
Intervention: ØREBLUE® Method
Description: The ØREBLUE® Method combines 2 inseparable therapeutic approaches that will be personalized, one dedicated to the auditory symptom (personalized sound therapy based on music and delivered through a helmet as part of the device), the other dedicated to the psychology of the subject.~Sound rehabilitation will be based on successive treatment sequences. The 1st sequence includes 30 hours of listening, at a rate of 2 hours / day, 5 days a week. A period of 4 to 6 weeks is necessary before carrying out a new sequence. The second sequence (and subsequent ones when necessary, respecting a 4-to-6-weeks window in between) of sound rehabilitation consists of 20 hours distributed as for the first sequence.

Intervention type: DEVICE
Intervention: ØREBLUE® Method
Description: The ØREBLUE® Method combines 2 inseparable therapeutic approaches that will be personalized, one dedicated to the auditory symptom (personalized sound therapy based on music and delivered through a helmet as part of the device), the other dedicated to the psychology of the subject.~Sound rehabilitation will be based on successive treatment sequences. The 1st sequence includes 30 hours of listening, at a rate of 2 hours / day, 5 days a week. A period of 4 to 6 weeks is necessary before carrying out a new sequence. The second sequence (and subsequent ones when necessary, respecting a 4-to-6-weeks window in between) of sound rehabilitation consists of 20 hours distributed as for the first sequence.
Study: NCT03852862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Serratus plane block and paravertebral block
Description: Single Administration of 20 mL of ropivacaine for Serratus plane block (Intra-muscular injection) followed by a single administration of 20 ml ropivacaine for paravertebral block (T4 inter-vertebral injection)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paravertebral block
Description: Single Administration of 20 ml of ropivacaine for paravertebral block (T4 inter-vertebral injection)
Study: NCT01124903

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Dehydration
Description: Subjects were dehydrated by 2 - 7% of body mass over 3-5 hours using exercise-heat stress and fluid restriction.
Study: NCT02384902

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low GI
Description: All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: low GI
Description: All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: conventional diet
Description: All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
Study: NCT01271192

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical resection and adjuvant therapy
Description: Postoperative:~Drug: fluorouracil Given IV continuously, Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Neoadjuvant followed by operation
Description: Preoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks~Postoperative:~Drug: fluorouracil Given IV continuously,Irinotecan Given IV
Study: NCT03184077

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laceration Repair with Polyglactin 910
Description: Polyglactin 910 suture for laceration repair

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laceration Repair with poliglecaprone 25
Description: poliglecaprone 25 suture for laceration repair
Study: NCT03574870

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearable sensor
Description: A commercially-available wearable fitness sensor

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: wearable sensor
Description: A commercially-available wearable fitness sensor
Study: NCT02813278

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: simo decoction
Description: Participants allocated to SMD and acupuncture were asked to take oral SMD decoction (Hansen Co., Ltd., Yiyang, Hunan province, China, 10 mL/dose) three times per day beginning on the first day after colorectal resection. They also received bilateral injections of vitamin B1 (50 mg x 2) at the tsusanli acupoint one time per day. This intervention was performed for a total of 5 consecutive days or until flatus.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: gum chewing
Description: Participants allocated to chewing gum were instructed to chew commercially available sugar-free gum (Extra \& Reg, Wm. Wrigley Jr. Co., Ltd., Shanghai, China) three times daily starting on the first postoperative morning. They were instructed to chew the piece of gum for at least 10 min. This intervention was performed for 5 consecutive days or until flatus.
Study: NCT06348485

Intervention type: OTHER
Intervention: Patients without massive nasal bleeding
Description: No event of massive nasal bleeding after curative radiotherapy

Intervention type: OTHER
Intervention: Patients with massive nasal bleeding
Description: Any event of massive nasal bleeding after curative radiotherapy
Study: NCT01982474

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Grass pollen extract
Description: Grass pollen extract injected intralymphatically q 4 weeks x 3

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Normal saline injected intralymphatically q 4 weeks x 3
Study: NCT02632396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV
Study: NCT04410588

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl + Topical Levobupivacaine
Description: in nasal packing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: levobupivacaine
Description: in nasal packing
Study: NCT02604953

Intervention type: DIAGNOSTIC_TEST
Intervention: Short Duration Transient Visual Evoked Potential (SDtVEP)
Description: Short duration transient visual evoked potentials (VEPs) detect disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex. As an objective measure of visual function, VEP may have advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.
Study: NCT05569083

Intervention type: DIAGNOSTIC_TEST
Intervention: ERP recording
Description: For ERP acquisition the same EEG system that was used for EEG data acquisition will be used. The participants will be administered an ERP test battery with concurrently recorded EEG consisting of a 3-choice vigilance task (3CVT) designed to evaluate sustained attention and standard image recognition memory task (SIR) designed to evaluate attention, encoding, and image recognition memory. In the SIR, images will be chosen as stimuli to distinguish short term from semantic memory loss and extend previous results of image recognition ERP effects.

Intervention type: DIAGNOSTIC_TEST
Intervention: ERP recording
Description: For ERP acquisition the same EEG system that was used for EEG data acquisition will be used. The participants will be administered an ERP test battery with concurrently recorded EEG consisting of a 3-choice vigilance task (3CVT) designed to evaluate sustained attention and standard image recognition memory task (SIR) designed to evaluate attention, encoding, and image recognition memory. In the SIR, images will be chosen as stimuli to distinguish short term from semantic memory loss and extend previous results of image recognition ERP effects.
Study: NCT02604953

Intervention type: DIAGNOSTIC_TEST
Intervention: Short Duration Transient Visual Evoked Potential (SDtVEP)
Description: Short duration transient visual evoked potentials (VEPs) detect disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex. As an objective measure of visual function, VEP may have advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.

Intervention type: DIAGNOSTIC_TEST
Intervention: Short Duration Transient Visual Evoked Potential (SDtVEP)
Description: Short duration transient visual evoked potentials (VEPs) detect disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex. As an objective measure of visual function, VEP may have advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pattern electroretinogram (PERG)
Description: Pattern electroretinogram (PERG), an objective test, is used for evaluating early damage to retinal ganglion cells (RGC). In PERG, retinal response is recorded while patterns are viewed in the visual field on a computer monitor.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pattern electroretinogram (PERG)
Description: Pattern electroretinogram (PERG), an objective test, is used for evaluating early damage to retinal ganglion cells (RGC). In PERG, retinal response is recorded while patterns are viewed in the visual field on a computer monitor.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pattern electroretinogram (PERG)
Description: Pattern electroretinogram (PERG), an objective test, is used for evaluating early damage to retinal ganglion cells (RGC). In PERG, retinal response is recorded while patterns are viewed in the visual field on a computer monitor.
Study: NCT00823849

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol
Description: From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probucol
Description: 250 mg Bid, PO after breakfast and dinner.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cilostazol+Probucol

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Control Group
Description: Routine treatment
Study: NCT03480568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alirocumab 150 MG/ML [Praluent]
Description: Cholesterol-lowering therapy
Study: NCT00841204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulindac
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Inactive agent

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00784290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orantinib (TSU-68)
Description: 200 or 400 mg bid day 1～day 28 cycle until progression or unacceptable toxicity develops
Study: NCT01212653

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simponi
Description: Golimumab 50mg monthly

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9ml sodium chloride
Description: 0.9ml sodium chloride
Study: NCT00820950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib phosphate cream
Description: Ruxolitinib phosphate cream 0.5%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovonex® calcipotriene 0.005%
Description: Cream applied once or twice daily for up to 56 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diprolene® AF betamethasone dipropionate 0.05% cream.
Description: Cream applied once or twice daily for up to 56 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo cream
Description: Cream applied once or twice daily for 56 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo cream
Description: Cream applied once or twice daily for 56 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo cream
Description: Cream applied once or twice daily for 56 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib phosphate cream
Description: Ruxolitinib phosphate cream 1.0%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib phosphate cream
Description: Ruxolitinib phosphate cream 1.5%
Study: NCT02917681

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Two intrathecal MSC injections
Study: NCT03972579

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Graded exposure therapy
Description: Gradually increased contact with avoided sensory stimuli (e.g., light, noise, movement) and activities (e.g., mental exertion, physical exercise, stressful activities) in order to increase tolerance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pacing + mindfulness
Description: Shifting from symptom-contingent to time-contingent activity stopping rules, minimizing activity level peaks (excessive endurance behavior) and valleys (prolonged periods of recuperative rest) to improve overall functioning.
Study: NCT01624259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2189265
Description: Administered SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin